188 related articles for article (PubMed ID: 24369094)
1. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.
Kirschbaum MH; Foon KA; Frankel P; Ruel C; Pulone B; Tuscano JM; Newman EM
Leuk Lymphoma; 2014 Oct; 55(10):2301-4. PubMed ID: 24369094
[TBL] [Abstract][Full Text] [Related]
2. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
[TBL] [Abstract][Full Text] [Related]
3. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
4. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.
Puvvada SD; Li H; Rimsza LM; Bernstein SH; Fisher RI; LeBlanc M; Schmelz M; Glinsmann-Gibson B; Miller TP; Maddox AM; Friedberg JW; Smith SM; Persky DO
Leuk Lymphoma; 2016 Oct; 57(10):2359-69. PubMed ID: 26758422
[TBL] [Abstract][Full Text] [Related]
6. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Campbell P; Thomas CM
J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
Mackay HJ; Hirte H; Colgan T; Covens A; MacAlpine K; Grenci P; Wang L; Mason J; Pham PA; Tsao MS; Pan J; Zwiebel J; Oza AM
Eur J Cancer; 2010 Jun; 46(9):1573-9. PubMed ID: 20304628
[TBL] [Abstract][Full Text] [Related]
8. Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
Walewski J; Paszkiewicz-Kozik E; Borsaru G; Hellmann A; Janikova A; Warszewska A; Mais A; Ammendola A; Herz T; Krauss B; Henning SW
Leuk Lymphoma; 2019 Mar; 60(3):675-684. PubMed ID: 30160566
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.
Yeo W; Chung HC; Chan SL; Wang LZ; Lim R; Picus J; Boyer M; Mo FK; Koh J; Rha SY; Hui EP; Jeung HC; Roh JK; Yu SC; To KF; Tao Q; Ma BB; Chan AW; Tong JH; Erlichman C; Chan AT; Goh BC
J Clin Oncol; 2012 Sep; 30(27):3361-7. PubMed ID: 22915658
[TBL] [Abstract][Full Text] [Related]
10. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
11. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
Ramalingam SS; Belani CP; Ruel C; Frankel P; Gitlitz B; Koczywas M; Espinoza-Delgado I; Gandara D
J Thorac Oncol; 2009 Jan; 4(1):97-101. PubMed ID: 19096314
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
Warlick ED; Cao Q; Miller J
Leukemia; 2013 Aug; 27(8):1789-91. PubMed ID: 23446311
[No Abstract] [Full Text] [Related]
14. Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.
Vey N; Prebet T; Thalamas C; Charbonnier A; Rey J; Kloos I; Liu E; Luan Y; Vezan R; Graef T; Recher C
Leuk Lymphoma; 2017 Aug; 58(8):1880-1886. PubMed ID: 27911138
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
Giaccone G; Rajan A; Berman A; Kelly RJ; Szabo E; Lopez-Chavez A; Trepel J; Lee MJ; Cao L; Espinoza-Delgado I; Spittler J; Loehrer PJ
J Clin Oncol; 2011 May; 29(15):2052-9. PubMed ID: 21502553
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML).
Kessler T; Koschmieder S; Schliemann C; Crysandt M; Mikesch JH; von Stillfried S; Stelljes M; Pohlen M; Lenz G; Kirsch A; Vehring K; Wardelmann E; Hartmann W; Bormann E; Gerss J; Brümmendorf TH; Müller-Tidow C; Berdel WE
Ann Hematol; 2019 Jun; 98(6):1393-1401. PubMed ID: 30903275
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
Hainsworth JD; Daugaard G; Lesimple T; Hübner G; Greco FA; Stahl MJ; Büschenfelde CM; Allouache D; Penel N; Knoblauch P; Fizazi KS
Cancer; 2015 May; 121(10):1654-61. PubMed ID: 25611313
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.
Shafer D; Kagan AB; Rudek MA; Kmieciak M; Tombes MB; Shrader E; Bandyopadhyay D; Hudson D; Sankala H; Weir C; Lancet JE; Grant S
Cancer Chemother Pharmacol; 2023 Mar; 91(3):281-290. PubMed ID: 36864346
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).
Cashen A; Juckett M; Jumonville A; Litzow M; Flynn PJ; Eckardt J; LaPlant B; Laumann K; Erlichman C; DiPersio J
Ann Hematol; 2012 Jan; 91(1):33-8. PubMed ID: 21538061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
